RPS welcomes new NHS training plans for community pharmacy

RPS welcomes new NHS training plans for community pharmacy

January 22 2018 Plans by the main NHS education organisation for England to expand training...

Wales updates strategy to improve respiratory health

Wales updates strategy to improve respiratory health

January 22 2018 An updated respiratory health plan for Wales has been published, taking forward...

Forthcoming Stay Well Pharmacy campaign flagged up

Forthcoming Stay Well Pharmacy campaign flagged up

January 22nd 2018 NHS England will launch a public health campaign promoting community pharmacies...

CPPE announces next accuracy checking pharmacy technician course

CPPE announces next accuracy checking pharmacy technician course

January 19 2018 Applications for the next intake of the accuracy checking pharmacy technician...

Community pharmacy set to have flu vaccine service recommissioned for 2018-19

Community pharmacy set to have flu vaccine service recommissioned for 2018-19

January 19 2017 A health minister has indicated that the community pharmacy flu vaccination...

  • RPS welcomes new NHS training plans for community pharmacy

    RPS welcomes new NHS training plans for community pharmacy

    Monday, 22 January 2018 14:48
  • Wales updates strategy to improve respiratory health

    Wales updates strategy to improve respiratory health

    Monday, 22 January 2018 14:45
  • Forthcoming Stay Well Pharmacy campaign flagged up

    Forthcoming Stay Well Pharmacy campaign flagged up

    Monday, 22 January 2018 14:41
  • CPPE announces next accuracy checking pharmacy technician course

    CPPE announces next accuracy checking pharmacy technician course

    Friday, 19 January 2018 17:32
  • Community pharmacy set to have flu vaccine service recommissioned for 2018-19

    Community pharmacy set to have flu vaccine service recommissioned for 2018-19

    Friday, 19 January 2018 17:15

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageJanuary 10 2018

The medicines regulator has highlighted the different strengths of co-dydramol in its latest Drug Safety Update. 

For many years co-dydramol has been available at a fixed ratio of 1:50, combining dihydrocodeine 10mg and paracetamol 500mg. However, the MHRA’s latest DSU is advising that new strengths containing greater amounts of dihydrocodeine – co-dydramol 20/500 mg and co-dydramol 30/500 mg tablets – are becoming available.

Health professionals should take care to ensure the intended strength is clearly prescribed and the correct strength is dispensed, says the MHRA. If the prescribed strength is unclear, the person dispensing should contact the prescriber for clarification. It is also asking that health professionals “report suspected adverse drug reactions with opioids, including any harm from medication error, via the Yellow Card Scheme.”

The January 6 DSU newsletter also asks health professionals to ask if a patient has been using herbal medicines when reporting any suspected adverse drug reaction. If herbal medicines or traditional Chinese medicines have been used, this information should be included on the Yellow Card scheme report.

Ideally, information about a herbal product should include the brand name, the list of ingredients, a copy of the package labelling if available, and any manufacturer details. Patients should also be advised to check for the Traditional Herbal Registration Certification Mark.

Another medicine included in the DSU newsletter is daclizumab (daclizumab beta), which is “now restricted to adults with relapsing multiple sclerosis who have had an inadequate response to at least two other disease-modifying therapies (DMTs) and for whom other DMTs are contraindicated or unsuitable.”

The MHRA is advising that patients with pre-existing hepatic disease or hepatic impairment should not use daclizumab. Caution should also be taken in prescribing daclizumab “in patients receiving other medication that may be hepatotoxic, including over-the-counter products and herbal medicines.”

Links:
MHRA Drug Safety Update: monthly PDF newsletters        
MHRA Drug Safety Update: monthly PDF newsletter. January 6 2018. 11;6.                 
Co-dydramol DSU             
Herbal medicines DSU    
Daclizumab DSU                

Practice News

January 22 2018 Plans by the main NHS education organisation for England to expand training programmes for community pharmacy have been welcomed by the Royal Pharmaceutical Society.
January 22nd 2018 NHS England will launch a public health campaign promoting community pharmacies to parents with young children next month.